Actively Recruiting

Age: 18Years - 100Years
All Genders
NCT07408219

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Led by Novartis Pharmaceuticals · Updated on 2026-05-11

350

Participants Needed

1

Research Sites

36 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.

CONDITIONS

Official Title

A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients

Who Can Participate

Age: 18Years - 100Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Healthcare providers must have an active medical license and be board certified or eligible allergists or dermatologists in the US; nurse practitioners and physician assistants practicing in allergy and dermatology are also eligible
  • Healthcare providers must manage CSU patients and agree to participate in the research network or be referred
  • Patients must be 18 years or older
  • Patients must have a diagnosis of chronic spontaneous urticaria by a healthcare provider
  • Patients must have received a prescription for remibrutinib or dupilumab and expect to start treatment
  • Patients must have access to an electronic device with internet
  • Patients must be able to read and understand English
  • Patients must be willing and able to provide consent for participation
Not Eligible

You will not qualify if you...

  • Patients unable to obtain remibrutinib or dupilumab through samples, commercial means, or assistance programs
  • Patients who used oral corticosteroids within 14 days before consent
  • Patients who used oral corticosteroids within 14 days before starting remibrutinib or dupilumab
  • Patients who previously participated in a remibrutinib or dupilumab clinical trial
  • Patients with cognitive impairment that affects their ability to participate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Novartis

East Hanover, New Jersey, United States, 07936

Actively Recruiting

Loading map...

Research Team

N

Novartis Pharmaceuticals

CONTACT

N

Novartis Pharmaceuticals

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here